First – line, non – cryopreserved autologous stem cell transplant for poor – risk germ – cell tumors: Experience in a developing country

Vol. 44 (x): 2018 September 9.[Ahead of print]

doi: 10.1590/S1677-5538.IBJU.2017.0562


ORIGINAL ARTICLE

Eucario Leon-Rodriguez 1, Monica M. Rivera-Franco 1, Dennis Lacayo-Leñero 2, Andrea Campos-Castro 2, Monica I. Meneses-Medina 3
1 Stem Cell Transplantation Program, Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; 2 Stem Cell Transplantation Program,Hematology Section, Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico; 3 Stem Cell Transplantation Program, Oncology Section, Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Mexico City, Mexico

ABSTRACT

Purpose: The current first – line treatment for non – seminomatous germ cell tumor (NSGCT) consists of four cycles of cisplatin, etoposide, and bleomycin (BEP), which results in 5 – year overall survival < 60% in patients with poor – risk features. Autolo­gous hematopoietic stem cell transplantation (auto – HSCT) as a method for overcom­ing high toxicity after high dose chemotherapy (HDC) has been explored in different solid tumors, but has remained standard practice only for NSGCT. Our objective was to describe outcomes of patients with poor – risk NSGCT who underwent first – line autologous HSCT in a tertiary center in Mexico.

Patients and Methods: Twenty nine consecutive patients with NSGCT who received first – line, non – cryopreserved autologous HSCT at the National Institute of Medical Sciences and Nutrition Salvador Zubiran in Mexico City, Mexico, from November 1998 to June 2016, were retrospectively analyzed.

Results: The median age at transplantation was 23 (15 – 39) years. Most patients (n = 18, 62%) had testicular primary tumor, and 23 had metastases (79%). Complete re­sponse after auto – HSCT was observed in 45%. Non – relapse mortality was 0. Five – year relapse / progression free and overall survival were 67% and 69%, respectively.

Conclusions: This small single limited – resource institution study demonstrated that patients with poor – risk NSGCT are curable by first – line HDC plus autologous HSCT and that this procedure is feasible and affordable to perform using non – cryopreserved hematopoietic stem cells.

Keywords: Stem Cell Transplantation; Neoplasms; Cryopreservation

[Full Text]


print

Related Post